Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings, Inc. reports developments in precision cardiovascular medicine, including AI-driven genetic and epigenetic blood tests for coronary heart disease. The company’s commercial products include Epi+Gen CHD, which assesses three-year risk for a coronary heart disease event, and PrecisionCHD, which aids in CHD diagnosis and management.
Recurring updates include clinical data for cardiovascular disease detection, CMS reimbursement and MolDX payment-rate activity, provider-network expansion, community health partnerships, and commercialization efforts for physician-ordered testing. Company communications also describe its Integrated Genetic-Epigenetic Engine and broader cardiovascular disease prevention, detection, and management strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.